Abstract of the Disclosure

The invention provides isolated dendritic cells genetically modified to express a selectin polypeptide, optionally treated with activated platelets or membrane microparticles thereof. The invention also provides isolated platelet modified dendritic cells. Methods for delivering the modified dendritic cells to peripheral lymph nodes and methods for using the modified dendritic cells to stimulate immune responses also are provided. Vaccine compositions containing the modified dendritic cells also are provided.